ASX:ADRAdherium Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adherium Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day RangeA$0.02MA: A$0.04▼A$0.0652-Week Range N/AVolume38,277 shsAverage VolumeN/AMarket Capitalization$8.35 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Adherium Limited develops, manufactures, and supplies digital health technologies that address sub-optimal medication use in chronic diseases in New Zealand, Australia, Europe, and North America. The company offers Hailie, an asthma and COPD medication adherence solution for patients with chronic respiratory diseases; and a range of smart medication sensors that automatically send usage data to a mobile app or PC via Bluetooth for respiratory medications. The company also provides Hailie mobile app, which provides real time reporting, monitoring, storing, and analysis of inhaler use. It offers its digital health solutions to patients, pharmaceutical companies, and healthcare providers. Adherium Limited was founded in 2001 and is based in Auckland, New Zealand.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Adherium. Previous Next 3.0 Community Rank Outperform VotesAdherium has received 15 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdherium has received 10 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdherium has received 60.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Adherium and other stocks. Vote “Outperform” if you believe ADR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdherium does not currently pay a dividend.Dividend GrowthAdherium does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adherium insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Adherium is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adherium is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.60 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolASX:ADR Previous Symbol CUSIPN/A CIKN/A Webwww.adherium.com Phone64 9 307 2771Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.21 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.00 Book ValueA($0.02) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares497,044,000Market Cap$8.35 million Next Earnings DateN/A OptionableNot Optionable Receive ADR News and Ratings via Email Sign-up to receive the latest news and ratings for ADR and its competitors with MarketBeat's FREE daily newsletter. Adherium (ASX:ADR) Frequently Asked Questions Has Adherium been receiving favorable news coverage? News headlines about ADR stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Adherium earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAdherium. Who are some of Adherium's key competitors? Some companies that are related to Adherium include Helius Medical Technologies (HSM), Oventus Medical (OVN), LBT Innovations (LBT), Impedimed (IPD), Titan Medical (TMD), Inspiration Healthcare Group (IHC), Azure Healthcare (AZV), Myomo (MYO), Surgical Innovations Group (SUN), Heramed (HMD), Myomo (MYO), Analytica (ALT), Xtant Medical (XTNT), Aurora Spine (ASG) and Osprey Medical (OSP). View all competitors. Who are Adherium's key executives? Adherium's management team includes the following people: Mr. Jeremy L. Curnock-Cook, Interim MD & Director (Age 69)Dr. William L. Hunter, Exec. Director (Age 56)Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, GAICD, GradDip CSP, FGIA, Joint Company Sec. (Age 55)Mr. Rob Turnbull, Gen. Mang. (Age 52)Mr. Chris Mander, Head of Regulatory & Quality What is Adherium's stock symbol? Adherium trades on the ASX under the ticker symbol "ADR." How big of a company is Adherium? Adherium has a market capitalization of $0.00 and generates $3.21 million in revenue each year. What is Adherium's official website? The official website for Adherium is www.adherium.com. How can I contact Adherium? The company can be reached via phone at 64 9 307 2771. This page was last updated on 5/27/2020 by MarketBeat.com Staff
